Compare NEXT & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NEXT | OCS |
|---|---|---|
| Founded | 2010 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | N/A | N/A |
| Metric | NEXT | OCS |
|---|---|---|
| Price | $5.26 | $26.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $9.00 | ★ $39.57 |
| AVG Volume (30 Days) | ★ 3.0M | 219.0K |
| Earning Date | 02-27-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $991,999.00 |
| Revenue This Year | N/A | $14.53 |
| Revenue Next Year | N/A | $691.13 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.76 | $14.00 |
| 52 Week High | $12.12 | $27.43 |
| Indicator | NEXT | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 49.30 | 80.02 |
| Support Level | $4.76 | $22.60 |
| Resistance Level | $5.56 | $27.43 |
| Average True Range (ATR) | 0.32 | 1.35 |
| MACD | 0.04 | 0.46 |
| Stochastic Oscillator | 62.89 | 90.92 |
NextDecade Corp is a Houston-based energy company engaged in construction and development activities related to the liquefaction of natural gas and sale of LNG and the capture and storage of CO2 emissions. The group is constructing and developing a natural gas liquefaction and export facility located in the Rio Grande Valley near Brownsville, Texas (the Rio Grande LNG Facility). It also engaged in NEXT Carbon Solutions advancing proprietary processes to lower the cost of utilizing carbon capture and storage (CCS) and help companies reduce their emissions and achieve their clean energy goals.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.